Profile data is unavailable for this security.
About the company
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
- Revenue in AUD (TTM)256.62k
- Net income in AUD-40.50m
- Incorporated1987
- Employees19.00
- LocationImmutep LtdPlaza Building, L 12 95 Pitt StSYDNEY NSW 2000AustraliaAUS
- Phone+61 28315-7003
- Fax+61 28569-1880
- Websitehttps://www.immutep.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dimerix Ltd | 181.28k | -10.87m | 272.09m | 0.00 | -- | 122.87 | -- | 1,500.93 | -0.0294 | -0.0294 | 0.0005 | 0.004 | 0.0169 | -- | 0.7586 | -- | -101.36 | -70.77 | -128.88 | -110.81 | -- | -- | -5,994.52 | -61,882.73 | -- | -- | 0.4541 | -- | 1,452.32 | 12.76 | -31.57 | -- | -8.26 | -- |
Race Oncology Ltd | 885.59k | -11.17m | 272.25m | -- | -- | 12.84 | -- | 307.42 | -0.069 | -0.069 | 0.0055 | 0.125 | 0.0336 | -- | 0.326 | -- | -42.44 | -43.50 | -43.67 | -45.25 | -- | -- | -1,261.86 | -5,058.82 | -- | -- | 0.00 | -- | 997.63 | 93.78 | 11.41 | -- | -- | -- |
Opthea Ltd | 175.09k | -241.64m | 324.78m | 5.00 | -- | -- | -- | 1,854.91 | -0.4631 | -0.4631 | 0.0003 | -0.1058 | 0.0007 | -- | 0.1772 | -- | -100.84 | -90.04 | -116.05 | -100.93 | -99.74 | -197.19 | -138,008.10 | -69,641.71 | -- | -29.64 | 1.35 | -- | 19.55 | -34.31 | -53.55 | -- | -3.82 | -- |
Mayne Pharma Group Ltd | 278.45m | -258.82m | 416.86m | 900.00 | -- | 0.7268 | -- | 1.50 | -3.18 | -2.99 | 3.43 | 6.74 | 0.2105 | 0.8192 | 1.37 | -- | -19.56 | -14.47 | -26.66 | -18.05 | 68.05 | 50.60 | -92.95 | -64.69 | 1.30 | -5.68 | 0.0626 | -- | 20.75 | -18.54 | -51.49 | -- | 18.41 | -- |
Imugene Ltd | 0.00 | -89.24m | 439.19m | 0.00 | -- | 2.21 | -- | -- | -0.0132 | -0.0132 | 0.00 | 0.0272 | 0.00 | -- | -- | -- | -40.29 | -26.64 | -43.53 | -28.00 | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -0.1207 | -- | -- | -- |
Botanix Pharmaceuticals Ltd | 200.38k | -10.02m | 448.91m | 1.00 | -- | 9.71 | -- | 2,240.31 | -0.0072 | -0.0072 | 0.0002 | 0.0293 | 0.0059 | -- | 1.09 | -- | -29.28 | -67.71 | -32.25 | -81.15 | -- | -- | -5,002.57 | -8,798.51 | 8.14 | -138.17 | 0.00 | -- | 351.94 | -6.25 | 30.50 | -- | -- | -- |
PYC Therapeutics Ltd | 21.54m | -21.65m | 489.94m | 23.00 | -- | 13.11 | -- | 22.74 | -0.006 | -0.006 | 0.0062 | 0.008 | 0.6034 | -- | 2.48 | -- | -60.70 | -41.67 | -81.23 | -46.95 | -- | -- | -100.60 | -178.69 | -- | -50.32 | 0.0174 | -- | -1.11 | 218.52 | -64.39 | -- | 18.46 | -- |
Immutep Ltd | 256.62k | -40.50m | 534.98m | 19.00 | -- | 4.63 | -- | 2,084.70 | -0.0394 | -0.0394 | 0.0003 | 0.0973 | 0.0025 | -- | 2.48 | -- | -38.61 | -36.31 | -41.57 | -39.21 | -- | -- | -15,782.59 | -919.13 | -- | -- | 0.0138 | -- | -24.64 | -51.34 | -23.86 | -- | 47.40 | -- |
Clinuvel Pharmaceuticals Limited | 87.29m | 30.15m | 731.52m | 16.00 | 25.07 | 4.10 | 23.49 | 8.38 | 0.5825 | 0.5825 | 1.69 | 3.56 | 0.4693 | -0.9514 | 7.35 | -- | 16.21 | 21.25 | 18.57 | 23.55 | 109.28 | -- | 34.54 | 41.84 | 6.43 | 14.53 | 0.006 | 7.44 | 24.27 | 26.14 | 46.58 | 18.27 | 68.74 | 20.11 |
Holder | Shares | % Held |
---|---|---|
Regal Funds Management Pty Ltd.as of 16 Feb 2024 | 88.01m | 7.40% |
Milford Asset Management Ltd.as of 13 Feb 2024 | 61.56m | 5.18% |
MLC Investments Ltd.as of 08 Jun 2023 | 55.64m | 4.68% |
Perennial Value Management Ltd.as of 07 Mar 2024 | 55.06m | 4.63% |
FIL Investment Management (Hong Kong) Ltd.as of 30 Apr 2024 | 46.68m | 3.93% |
Australian Ethical Investments Ltd. (Investment Management)as of 03 Oct 2022 | 44.14m | 3.71% |
Antares Capital Partners Ltd.as of 08 Jun 2023 | 24.95m | 2.10% |
HB Biotechnology Ltd.as of 22 Aug 2023 | 6.48m | 0.55% |
DFA Australia Ltd.as of 30 Apr 2024 | 5.97m | 0.50% |
Endeavor Asset Management Pty Ltd.as of 22 Aug 2023 | 4.98m | 0.42% |